A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
Latest Information Update: 16 Jan 2020
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms ENDURANCE-5,6
- Sponsors AbbVie
- 01 Dec 2018 Results of a pooled post-hoc analysis from ENDURANCE-1, 2, 3, 4, 5 studies, published in the Infectious Diseases and Therapy
- 13 Nov 2018 Final results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 30 Aug 2018 Status changed from active, no longer recruiting to completed.